Status:
COMPLETED
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Lead Sponsor:
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-1...
Detailed Description
In late 2019, an unidentified viral pneumonia was detected in Wuhan, China. Later, it was declared that it was pneumonia due to a new coronavirus. The World Health Organization (WHO) officially called...
Eligibility Criteria
Inclusion
- Diagnosis of acute severe respiratory syndrome due to SARS-CoV-12 coronavirus infection defined by RT-PCR.
- Asymptomatic, or with mild symptoms who are taking outpatient treatment of the disease.
- Signed Informed Consent.
Exclusion
- Patients with severe disease COVID-19.
- Positive to proof of infection by some other virus such as influenza H1N1, SARS, etc.
- Recurrent urinary tract infections.
- Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)\> 5 times above its normal limits.
- Pregnant or lactating patients
- Patients receiving antihypertensive medication verapamil, the immunosuppressant cyclosporin A and / or the antipsychotic trifluoperazine.
- Patients with a known allergy or hypersensitivity to dewormers.
- Patients who are using an antioxidant supplement.
- Patients with a history of filariasis, strongyloidiasis, scabies, river blindness, or any parasitic disease in the last twelve months.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04407507
Start Date
July 1 2020
End Date
January 29 2021
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigacion Biomédica para el Desarrollo de Fármacos S.A. de C.V.
Zapopan, Jalisco, Mexico